On Friday, June 15, 2007, the U.S. Food and Drug Administration (FDA) gave marketing approval to Letairis (ambrisentan) for the treatment of pulmonary arterial hypertension, a dangerous condition in which blood pressure increases in the arteries in the lungs. According to the FDA, about 100,000 people in the United States have pulmonary arterial hypertension. Letairis was shown to be safe and effective in two international clinical trials. It is not approved for use during pregnancy. Side effects may include swelling (edema) of legs and ankles, nasal congestion, sinusitis, and getting red in the face (flushing).
U.S. FDA approves orphan drug Letairis for pulmonary hypertension
From Mary Kugler, R.N., About.com GuideJune 19, 2007
On Friday, June 15, 2007, the U.S. Food and Drug Administration (FDA) gave marketing approval to Letairis (ambrisentan) for the treatment of pulmonary arterial hypertension, a dangerous condition in which blood pressure increases in the arteries in the lungs. According to the FDA, about 100,000 people in the United States have pulmonary arterial hypertension. Letairis was shown to be safe and effective in two international clinical trials. It is not approved for use during pregnancy. Side effects may include swelling (edema) of legs and ankles, nasal congestion, sinusitis, and getting red in the face (flushing).
Explore Rare Diseases
My dad has been on this medication for about 5 mos. now. His ankles and legs have so much edema it is difficult for him to walk. His dr. says its because he had a bowl of chicken soup. I would like to know if this is something I need to bring up with her. I see NO improvement in my dads breathing at all, actually I think he gets winded more.. Please let me know what you think.
ive been on letairis now for 9 months . still no improvement . my pulmonary pressures measured in at 110